CNS Pharmaceuticals, Inc.
CNSP
$6.66
$0.152.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.95% | 13.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.03% | -44.45% | |||
| Operating Income | -35.03% | 44.45% | |||
| Income Before Tax | -35.52% | 44.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.52% | 44.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.52% | 44.78% | |||
| EBIT | -35.03% | 44.45% | |||
| EBITDA | -35.06% | 44.47% | |||
| EPS Basic | 10.25% | 66.10% | |||
| Normalized Basic EPS | 10.25% | 66.10% | |||
| EPS Diluted | 10.28% | 66.14% | |||
| Normalized Diluted EPS | 10.25% | 66.10% | |||
| Average Basic Shares Outstanding | 51.01% | 62.90% | |||
| Average Diluted Shares Outstanding | 51.01% | 62.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||